– Enlarged Phase 2 Study to Begin in 2018 for Potential Acute Treatment of Hereditary Angioedema; Data Expected in Late 2019 – – Food Effect Study Indicates No Dosing Limitations from Food and Confirms Rapid Uptake and High Exposure – CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Nov....

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Nov. 6, 2018-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present a...

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Sep. 25, 2018-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present at...

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)-- – KVD900 Phase 2 On Track to Begin in 2018 for Potential On-Demand Treatment of Acute Attacks in Patients with Hereditary Angioedema – – Intravitreal Diabetic Macular Edema Candidate KVD001 Enrollment On Track with Data Expected in H2 2019 –...

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Sep. 10, 2018-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors, today announced the closing of its...

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Sep. 6, 2018-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors, today announced the pricing of its

...

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Sep. 5, 2018-- KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors, announced today that it intends to offer

...

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--Aug. 7, 2018-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present a

...

– KVD900 Selected to Advance to Phase 2 as Potential On-Demand Treatment of Acute Attacks in Patients with Hereditary Angioedema (HAE) – – KVD001 Phase 2 Clinical Trial for Patients with Diabetic Macular Edema (DME) Enrollment Remains on Track with Data Expected in H2 2019 – – $14.6 Million

...

CAMBRIDGE, Mass. & SALISBURY, England --(BUSINESS WIRE)--May 31, 2018-- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today announced that it will present a...